Therapeutic area
Oncology
Cancers and their treatment, spanning solid tumors and hematologic malignancies -- addressed one tumor type at a time given how sharply drug development fragments by biomarker/molecular subtype within a single cancer.
Diseases
Acute Myeloid Leukemia
$4.3B attributable cost
127 assets · 1 indication
HR+/HER2- Breast Cancer
$22.7B attributable cost
$2.4B drug spend
103 assets · 1 indication
Multiple Myeloma
$13.7B attributable cost
$6.7B drug spend
168 assets · 1 indication
Non-Small Cell Lung Cancer
$12.5B attributable cost
$4.8B drug spend
624 assets · 1 indication